By Stephen Nakrosis

Teva Pharmaceutical Industries Ltd. (TEVA) said Thursday it was launching a generic version of Tarceva, or erlotinib, tablets in the U.S.

Erlotinib tablets are a kinase inhibitor indicated for the treatment of certain patients with metastatic non-small cell lung cancer, Teva said. Erlotinib tablets are also indicated for first-line treatment of certain patients with pancreatic cancer.

Tarceva is distributed in the U.S. by Astellas Pharma U.S. in partnership with Genentech, a member of The Roche Group.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

May 09, 2019 17:16 ET (21:16 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Teva Pharmaceutical Indu... Charts.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Teva Pharmaceutical Indu... Charts.